Form 4: Sight Sciences CFO Receives RSU Grant

Sight Sciences' Chief Financial Officer, James Rodberg, was granted 15,337 restricted stock units, valued at approximately $100,000, under the company's 2021 Incentive Award Plan.

Summary

• James Rodberg, Chief Financial Officer of Sight Sciences, Inc. (SGHT), received a grant of 15,337 restricted stock units (RSUs).
• The grant was made on November 11, 2025, under the Issuer's 2021 Incentive Award Plan.
• The RSUs represent a contingent right to receive one share of common stock for each unit.
• The number of RSUs granted is approximately equivalent to $100,000 of common stock based on the stock price on the grant date.
• The RSUs will vest in 16 equal quarterly installments, starting December 31, 2025, and concluding on September 30, 2029.
• Vesting is contingent upon Mr. Rodberg's continued service to the Issuer through each vesting date.
• Following this transaction, Mr. Rodberg beneficially owns 161,363 shares of common stock.

Sentiment

Score: 6

Explanation: Slightly positive. This is a routine executive compensation event that aligns management's interests with shareholders, which is generally viewed favorably, though it introduces minor future dilution.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained performance.
• The vesting schedule over several years promotes executive retention and commitment to the company's long-term strategic goals.

Negatives

• The issuance of new shares upon vesting of RSUs will result in a minor dilution of existing shareholder equity.

Risks

• The value of the RSUs to the reporting person is subject to the future market price of Sight Sciences, Inc. common stock.
• Vesting is contingent on continued service, meaning the reporting person may forfeit unvested units if employment ceases.

Future Outlook

The vesting schedule for the RSUs extends through September 30, 2029, indicating an expectation of continued service from the Chief Financial Officer and a long-term incentive structure tied to the company's performance over this period.

Industry Context

The grant of restricted stock units to a key executive like the Chief Financial Officer is a standard practice in the biotechnology and medical device industry, as well as across publicly traded companies, to attract, retain, and motivate top talent by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule is a common and widely accepted form of executive compensation across various industries, including healthcare and technology, similar to practices seen at companies like Medtronic, Intuitive Surgical, or Boston Scientific.
• The grant size, approximately $100,000, for a CFO, while not explicitly compared to peers in the filing, falls within typical ranges for annual equity grants, depending on company size, performance, and overall compensation philosophy.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting; improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.

Next Steps

• The granted RSUs will begin vesting in 16 equal quarterly installments starting December 31, 2025.
• The vesting process will continue through September 30, 2029, contingent on the CFO's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain new material information that would fundamentally alter the investment thesis for Sight Sciences, Inc. It is a standard practice to align executive interests with shareholders, and as such, it is unlikely to significantly impact the stock price or warrant a change in investment recommendation based solely on this filing.

Keywords

Sight Sciences, SGHT, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, James Rodberg, CFO, Equity Incentive Plan